Ahmed Othman Almailabi, Ali Mohammed Nassir Alshaikhi, May Motea Sado Sahyoun, M. M. Algarni, Ali Hebni Ali Alshehri, Wael Seddiq Mosa Elagi, AbdulKarim Matar Aun Alsulami, Iprahim Ahmed Alzahrani, Ahmad mohammad Alghamdi, Yasser ali Alharbi, Faisal matar Al anazi anazi
{"title":"AN OVERVIEW PHARMACIST'S ROLE IN PREVENTING MEASURES TOWARD ANTIBIOTIC RESISTANCE","authors":"Ahmed Othman Almailabi, Ali Mohammed Nassir Alshaikhi, May Motea Sado Sahyoun, M. M. Algarni, Ali Hebni Ali Alshehri, Wael Seddiq Mosa Elagi, AbdulKarim Matar Aun Alsulami, Iprahim Ahmed Alzahrani, Ahmad mohammad Alghamdi, Yasser ali Alharbi, Faisal matar Al anazi anazi","doi":"10.53555/jptcp.v30i2.4683","DOIUrl":null,"url":null,"abstract":"The issue of antimicrobial medication resistance is a significant global concern. Drug discovery plays a crucial role in addressing present treatment gaps and enhancing established therapeutic methods. However, due to the extensive research duration and substantial expenses involved in introducing novel drugs to the market, focusing on the development of new drugs that target drug-resistant microbes with harmful effects may not be the most optimal approach. The literature was systematically evaluatesing databases to identify all relevant research published until the beginning of 2022. In order to uncover novel classes of antibiotics, there is a pressing need for the development of innovative methodologies in rational design and screening-based approaches. The advancement of efficient molecular methodologies for the identification of resistance genes, as well as the exploration of diagnostic biomarkers such as procalcitonin for the purpose of guiding the discontinuation of antibiotic treatment, holds significant value in the effort to mitigate antibiotic usage.","PeriodicalId":504389,"journal":{"name":"Journal of Population and Therapeutics and Clinical Pharmacology","volume":"13 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Population and Therapeutics and Clinical Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53555/jptcp.v30i2.4683","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The issue of antimicrobial medication resistance is a significant global concern. Drug discovery plays a crucial role in addressing present treatment gaps and enhancing established therapeutic methods. However, due to the extensive research duration and substantial expenses involved in introducing novel drugs to the market, focusing on the development of new drugs that target drug-resistant microbes with harmful effects may not be the most optimal approach. The literature was systematically evaluatesing databases to identify all relevant research published until the beginning of 2022. In order to uncover novel classes of antibiotics, there is a pressing need for the development of innovative methodologies in rational design and screening-based approaches. The advancement of efficient molecular methodologies for the identification of resistance genes, as well as the exploration of diagnostic biomarkers such as procalcitonin for the purpose of guiding the discontinuation of antibiotic treatment, holds significant value in the effort to mitigate antibiotic usage.